The Advent of More Potent ALK Inhibitors
Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.
Clinical Pearls
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors and the treatment of ALK-positive lung cancer patients with crizotinib.
- The treatment of these patients is more complicated now, with the advent of more potent ALK inhibitors
- New ALK inhibitors are potent in patients both resistant and naive to crizotinib
- At a large cancer center, the option exists to start crizotinib as standard therapy or consider a clinical trial with a next-generation ALK inhibitor
- In the community setting, standard procedure would be to start a newly-diagnosed ALK-positive patient on crizotinib
Recent Videos
Related Content
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024Article
In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
